Edition:
India

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

193.50USD
9:15pm IST
Change (% chg)

$0.01 (+0.01%)
Prev Close
$193.49
Open
$191.66
Day's High
$193.62
Day's Low
$191.02
Volume
18,698
Avg. Vol
106,391
52-wk High
$201.01
52-wk Low
$114.84

Latest Key Developments (Source: Significant Developments)

Ligand Prices Offering Of $650 Mln Of Convertible Senior Notes
Friday, 18 May 2018 

May 18 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND PRICES OFFERING OF $650 MILLION OF CONVERTIBLE SENIOR NOTES.LIGAND PHARMACEUTICALS INC - PRICING OF $650 MILLION AGGREGATE PRINCIPAL AMOUNT OF 0.75% CONVERTIBLE SENIOR NOTES DUE 2023.LIGAND PHARMACEUTICALS INC - CONVERSION RATE FOR NOTES WILL INITIALLY BE 4.0244 SHARES PER $1,000 PRINCIPAL AMOUNT OF NOTES.  Full Article

Ligand Pharmaceuticals Announces Proposed Offering Of $650 Mln Of Convertible Senior Notes
Thursday, 17 May 2018 

May 16 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND ANNOUNCES PROPOSED OFFERING OF $650 MILLION OF CONVERTIBLE SENIOR NOTES.LIGAND PHARMACEUTICALS INC - INTENDS TO OFFER $650 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2023 IN A PRIVATE OFFERING.LIGAND PHARMACEUTICALS - INTENDS TO USE PORTION OF NET PROCEEDS FROM OFFERING OF NOTES TO PAY COST OF CERTAIN CONVERTIBLE NOTE HEDGE TRANSACTIONS.LIGAND PHARMACEUTICALS - TO USE PROCEEDS FROM OFFERING ALSO TO BUYBACK UP TO $50 MILLION OF CO'S SHARES FROM BUYERS OF NOTES IN PRIVATELY NEGOTIATED DEALS.  Full Article

Ligand Pharma Says Co Sent Computershare, As Rights Agent Under Glucagon CVR Agreement
Friday, 13 Apr 2018 

April 13 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND PHARMACEUTICALS SAYS HOLDERS OF GLUCAGON CVRS ENTITLED TO RECEIVE PRO RATA $3.8 MILLION.  Full Article

Ligand Pharma Says‍ Underreported Potential Aggregate Milestone Payments Related To License Agreement With Roivant Sciences
Wednesday, 7 Mar 2018 

March 7 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND PHARMACEUTICALS SAYS‍ UNDERREPORTED POTENTIAL AGGREGATE MILESTONE PAYMENTS RELATED TO LICENSE AGREEMENT WITH ROIVANT SCIENCES FOR LGD-6972​.LIGAND PHARMA SAYS UNDER AGREEMENT, CO TO RECEIVE POTENTIAL LICENSE & MILESTONE PAYMENTS OF UP TO $548.8 MILLION - SEC FILING.  Full Article

Ligand Pharma Signs License Agreement
Wednesday, 7 Mar 2018 

March 6 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND PHARMACEUTICALS INC - SIGNED LICENSE AGREEMENT GRANTING ROIVANT SCIENCES EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE LGD-6972.  Full Article

Ferring Says Specific Financial Details Of Transaction With Ligand Pharma Are Not Disclosed​
Monday, 22 Jan 2018 

Jan 22 (Reuters) - ‍Ferring Pharmaceuticals::FERRING ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH LIGAND.‍FERRING PHARMACEUTICALS SAYS SPECIFIC FINANCIAL DETAILS OF TRANSACTION WITH LIGAND PHARMA ARE NOT DISCLOSED​.  Full Article

Ligand Enters Into Worldwide Omniab Platform License Agreement With Ferring Pharmaceuticals
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH FERRING PHARMACEUTICALS.LIGAND PHARMACEUTICALS INC - ‍UNDER LICENSE, FERRING WILL BE ABLE TO USE FULL OMNIAB PLATFORM TO DISCOVER FULLY HUMAN MONO- AND BISPECIFIC ANTIBODIES​.LIGAND PHARMACEUTICALS INC - ‍FERRING WILL BE RESPONSIBLE FOR ALL COSTS RELATED TO PROGRAMS​.LIGAND PHARMACEUTICALS-WITH DEAL WITH FERRING, CO‍ ELIGIBLE TO RECEIVE ANNUAL PLATFORM ACCESS PAYMENTS, DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS​.  Full Article

Ligand Pharma And Glenmark Pharma Enter Into License Agreement
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH GLENMARK PHARMACEUTICALS.LIGAND PHARMACEUTICALS - ‍ UNDER LICENSE, GLENMARK WILL BE ABLE TO USE FULL OMNIAB PLATFORM TO DISCOVER FULLY HUMAN MONO- AND MULTISPECIFIC ANTIBODIES​.LIGAND PHARMACEUTICALS INC - ‍GLENMARK WILL BE RESPONSIBLE FOR ALL COSTS RELATED TO PROGRAMS​.LIGAND - ELIGIBLE TO RECEIVE ANNUAL PLATFORM ACCESS PAYMENTS, REGULATORY MILESTONE PAYMENTS, AMONG OTHERS, FOR PRODUCTS INCORPORATING OMNIAB ANTIBODY​.  Full Article

Ligand Earns $6 Million As Omniab Partner Out-Licenses Antibody Projects
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND EARNS $6 MILLION AS OMNIAB PARTNER OUT-LICENSES ANTIBODY PROJECTS.SEES FY 2017 ADJUSTED EARNINGS PER SHARE $3.13 TO $3.16.SEES FY 2017 REVENUE ABOUT $140 MILLION.  Full Article

Ligand Pharma reaffirms 2017 revenue guidance between $134 mln and $136 mln
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Ligand Pharmaceuticals Inc :Ligand Pharmaceuticals-reaffirmed full-year 2017 revenue guidance of between $134 million and $136 million and adjusted EPS guidance of between $2.95 to $3.00​.Ligand Pharmaceuticals Inc - ‍currently believes potential royalty revenue growth for 2018 could be in range of 15% to 25% over that of full year 2017​.Ligand Pharmaceuticals Inc - ‍full-year 2018 corporate gross margin is expected to be in range of 94% to 96%​.  Full Article

BRIEF-Ligand Pharmaceuticals Entered Commercial Platform License Agreement, With KSQ Therapeutics

* LIGAND PHARMACEUTICALS - ON MAY 8, ENTERED COMMERCIAL PLATFORM LICENSE AGREEMENT, WITH KSQ THERAPEUTICS, INC - SEC FILING